IP Library Granted Patent US 8,318,716
Granted Patent B2
US 8,318,716 · App. 12/650,742 · Granted Nov 27, 2012

Carbapenem derivatives

Assignee: KBP Biosciences Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,318,716
App. No.
12/650,742
Granted
Nov 27, 2012
Kind
B2
Abstract

The present invention includes novel carbapenem derivatives having structural formula (I) or (II): wherein R 1 , R 2 , R 3 , R 4 are described in the specification. The present invention also provides pharmaceutical compositions comprising the novel carbapenem derivatives and the use of the novel carbapenem derivatives for treating infectious diseases.

Claims (46)

1. A compound of formula (I):

or a pharmaceutically acceptable salt, ester, and/or prodrug thereof;

wherein

R 1 is hydrogen or a carboxyl protecting group;

R 2 is hydrogen or an amino-protecting group;

R 3 is hydrogen or lower alkyl; and

R 4 is phenyl or substituted phenyl;

wherein the substituted phenyl comprises one or more substituents selected from the group consisting of halogen; hydroxyl; carboxyl; amino; nitro; cyano; lower alkyl; substituted lower alkyl; lower alkoxy; substituted lower alkoxy; aminosulfonyl; lower alkylaminosulfonyl; and a combination thereof;

wherein the substituted lower alkyl and the substituted lower alkoxy each independently comprise one or more substituents selected from the group consisting of halogen; hydroxyl; carboxyl; amino; nitro; cyano; and a combination thereof.

2. A compound of formula (I):

or a pharmaceutically acceptable salt, ester, and/or prodrug thereof;

wherein

R 1 is a hydrogen atom or a carboxyl protecting group;

R 2 is a hydrogen atom or an amino-protecting group;

R 3 is a hydrogen atom or a lower alkyl; and

R 4 is a phenyl or substituted phenyl;

wherein the substituted phenyl comprises one or more substituents selected from the group consisting of sulfo; carbamoyl; lower alkyl; substituted lower alkyl; lower alkoxy; substituted lower alkoxy; lower alkylcarbonyl; substituted lower alkylcarbonyl; lower alkylcarbonyloxy; substituted lower alkylcarbonyloxy; lower alkylsulphonyl; substituted lower alkylsulphonyl; lower alkylamido; substituted lower alkylamido; lower alkylcarbamoyl; substituted lower alkylcarbamoyl; lower alkylsulphonamido; substituted lower alkylsulphonamido; and a combination thereof;

wherein the substituted lower alkyl and the substituted lower alkoxy each independently comprise one or more substituents selected from the group consisting of sulfo; aminosulphonyl; carbamoyl; and a combination thereof;

wherein the substituted lower alkylcarbonyl; the substituted lower alkylcarbonyloxy; the substituted lower alkylsulphonyl; the substituted lower alkylamido; the substituted lower alkylcarbamoyl; and the substituted lower alkylsulphonamido each independently comprise one or more substituents selected from the group consisting of halogen; hydroxyl; carboxyl; amino; nitro; cyano; sulfo; aminosulfonyl; carbamoyl; and a combination thereof.

3. A compound of formula (II):

or a pharmaceutically acceptable salt, ester, and/or prodrug thereof;

wherein

R 1 is a hydrogen atom or a carboxyl protecting group;

R 2 is a hydrogen atom or an amino-protecting group;

R 3 is a hydrogen atom or a lower alkyl; and

R 4 is a phenyl or substituted phenyl;

wherein the substituted phenyl comprises one or more substituents selected from the group consisting of sulfo; carbamoyl; lower alkyl; substituted lower alkyl; lower alkoxy; substituted lower alkoxy; lower alkylcarbonyl; substituted lower alkylcarbonyl; lower alkylcarbonyloxy; substituted lower alkylcarbonyloxy; lower alkylsulphonyl; substituted lower alkylsulphonyl; lower alkylamido; substituted lower alkylamido; lower alkylcarbamoyl; substituted lower alkylcarbamoyl; lower alkylsulphonamido; substituted lower alkylsulphonamido; and a combination thereof;

wherein the substituted lower alkyl and the substituted lower alkoxy each independently comprise one or more substituents selected from the group consisting of sulfo; aminosulphonyl; carbamoyl; and a combination thereof;

wherein the substituted lower alkylcarbonyl; the substituted lower alkylcarbonyloxy; the substituted lower alkylsulphonyl; the substituted lower alkylamido; the substituted lower alkylcarbamoyl; and the substituted lower alkylsulphonamido each independently comprise one or more substituents selected from the group consisting of halogen; hydroxyl; carboxyl; amino; nitro; cyano; sulfo; aminosulfonyl; carbamoyl; and a combination thereof.

4. The compound of any of claims 1 to 3 , wherein

R 3 is hydrogen, methyl, ethyl, or propyl;

R 4 is a phenyl or substituted phenyl;

wherein the substituted phenyl comprises one or more substituents selected from the group consisting of halogen; hydroxyl; carboxyl; amino; lower alkyl; substituted lower alkyl; lower alkoxy; substituted lower alkoxy; aminosulfonyl; and a combination thereof;

wherein the substituted lower alkyl and the substituted lower alkoxy each independently comprise one or more substituents selected from the group consisting of halogen; hydroxyl; carboxyl; amino; and a combination thereof.

5. The compound of any of claims 1 to 3 , wherein

R 1 represents hydrogen atom;

R 2 represents hydrogen atom;

R 3 represents hydrogen atom or methyl;

R 4 is a phenyl or substituted phenyl;

wherein the substituted phenyl comprises one or more substituents selected from the group consisting of methyl; ethyl; carboxyl; carboxymethyl; carboxyethyl; methoxy; trifluoromethoxy; aminosulfonyl; and a combination thereof.

6. The compound of any of claims 1 to 3 , which is selected from the group consisting of

or a pharmaceutically acceptable salt, ester, and/or prodrug thereof.

7. The compound of any of claims 1 to 3 , wherein the pharmaceutically acceptable salt is an amino acid salt, or an inorganic base salt.

8. The compound of any of claims 1 to 3 , wherein the pharmaceutically acceptable ester is hydrolyzable to the corresponding carboxylic acid in vivo.

9. A pharmaceutical composition comprising a compound of any of claims 1 to 3 , or a pharmaceutically acceptable salt, ester, and/or prodrug thereof; and one or more pharmaceutically acceptable carriers.

10. A method of treating a bacterial infection in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of any of claims 1 to 3 , or a pharmaceutically acceptable salt, ester, and/or prodrug thereof.

Assignments (6)
CHANGE OF NAME Recorded Jan 16, 2021
From: HAINAN XUANZHU PHARMA CO., LTD.
To: XUANZHU (HAINAN) BIOPHARMACEUTICAL CO., LTD.
Reel/Frame 055012/0869 →
CHANGE OF NAME Recorded Jan 16, 2021
From: XUANZHU (HAINAN) BIOPHARMACEUTICAL CO., LTD.
To: XUANZHU (SHIJIAZHUANG) BIOPHARMACEUTICAL CO., LTD.
Reel/Frame 055012/0872 →
CHANGE OF NAME Recorded Jan 16, 2021
From: XUANZHU (SHIJIAZHUANG) BIOPHARMACEUTICAL CO., LTD.
To: XUANZHU BIOPHARMACEUTICAL CO., LTD.
Reel/Frame 055012/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2019
From: XUANZHU PHARMA CO., LTD.
To: HAINAN XUANZHU PHARMA CO., LTD.
Reel/Frame 048267/0354 →
CHANGE OF NAME Recorded Nov 8, 2013
From: KBP BIOSCIENCES CO., LTD.
To: XUANZHU PHARMA CO., LTD.
Reel/Frame 031608/0749 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2010
From: HUANG, ZHENHUA; DONG, YANYAN
To: KBP BIOSCIENCES CO., LTD.
Reel/Frame 024146/0952 →
Continuity (1)
Related Publication 20110160177A1 · Jun 30, 2011